IFNA1 and liver disorder: Outcomes among PWID are unknown, but systematic reviews report similar response rates among PWID and non-PWID for IFN+RBV regimens.48,49 Additionally, active PWID are generally younger (a meta-analysis48 found a lower median age (38 years) for studies with HCV treatment among PWID compared with registration trials for PEG-IFN+RBV (43-45 years)) and have less advanced liver disease than the broader HCV population.